

Serial No.: 10/695,574 Replacement Sheet 12 Docket No.: 1003-DIV-01

## FIG. 12 STABILIZING EFFECTS OF THE POLYMERS ON FGF1

	Γ	<u> </u>				1
TREATMENT	20°C	20°C	20°C	20°C	37°C	37°C
VALUE ED50	0 DAYS	1 DAY	7 DAYS	15 DAYS	1 DAY	7 DAYS
FGF1 ALONE	6	8	14	>20	7	>20
FGF1 + Heparin	0.8	1.2	6	16	1.4	15
FGF1 + Dextran T40	6	10	>20	>20	7	>20
FGF1 + DS commercial	6	8	>20	>20	7	>20
FGF1 + DS <sub>0.5</sub> equiv	6	8	>20	>20	7	>20
FGF1 + DS <sub>0.125</sub> equiv	6	10	>20	>20	7	>20
Pcoo-	8	>20	>20	>20	18	>20
P1S	3	6	10	17	5	15
P2S	1	3	9	14	3	11
FGF1 + CM <sub>1</sub> D	6	9	>20	>20	7	>20
FGF1 + CM <sub>2</sub> D	6	.7	>20	>20	7	>20
FGF1 + CM <sub>1</sub> DS2	0.5	1.1	6	17	2.1	16
FGF1 + CM <sub>2</sub> DS2	2	8	15	>20	5	>20
FGF1 + CM <sub>2</sub> DPhS	8	15	>20	>20	8	>20
FGF1 + CM <sub>2</sub> DPhSS1	2	6	18	>20	3	14
FGF1 + CM <sub>2</sub> DES1	1	3	8	17	9	>20
FGF1 + CM <sub>2</sub> DPheS2	0.9	2	4	13	8	17
FGF1 + CM <sub>3</sub> DTyrS2	3	5	>20	>20	9	>20
FGF1 + CM <sub>1</sub> DPalmS1	4	4	16	>20	14	>20

BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

Inventors: Denis Barritault et al. Serial No.: 10/695,574 Replacement Sheet 13 Docket No.: 1003-DIV-01

FIG. 13
POTENTIATION EFFECTS ON FGF1 AND FGF2

Reference polymers	Conditions	concentrations (µg/ml)	ED50 FGF1 ( ng/ml)	ED50 FGF2 ( pg/ml)
	FGF ALONE	0	8	56
	Heparin	1	2	35
RGTA 2010	Pcoo-	100	4	56
RGTA 2011	P1S	100	2.5	38
RGTA 2012	P2S	100	4	41
RGTA 0040	DS commmercial	100	3	30
RGTA 1024	DS <sub>0.5</sub> equiv	100	. 4	36
RGTA 1026	DS <sub>0.125</sub> equiv	100	6	48
RGTA 1000	CM <sub>1</sub> D	10	12	168
RGTA 1007	CM <sub>2</sub> D	10	16	297
RGTA 1005	CM <sub>2</sub> DS2	10	1	40
RGTA 1012	CM <sub>2</sub> DS2	10	1.5	31
RGTA 1110	CM <sub>1</sub> DPhS1	10	8	53
RGTA 1111	CM <sub>2</sub> DES1	10	5	45
RGTA 1112	CM <sub>2</sub> DPheS2	10	3	38
RGTA 1113	CM <sub>3</sub> DTyrS2	10	2	30
RGTA 1114	CM <sub>1</sub> DPalmS1	10	9	42

BIOCOMPATIBLE POLYMERS, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM

Inventors: Denis Barritault et al. Serial No.: 10/695,574 Replacement Sheet 16 Docket No.: 1003-DIV-01

FIG. 16

## INHIBITORY EFFECTS OF THE POLYMERS ON THE ACTIVITIES OF LEUKOCYTE ELASTASE AND PLASMIN

	IC 50	mg/ml	]	IC 50	ma/ml
					mg/ml
Polymers	Elastase	plasmin	Polymers	Elastase	plasmin
Heparin	1.8	1	CM <sub>2</sub> DSex	5	0.07
Pcoo-	100	53	CM <sub>3</sub> D	>100	>100
P1S	2	0.98	CM <sub>3</sub> DS <sub>0.5</sub>	8	6
P2S	4.7	0.82	CM <sub>3</sub> DS <sub>1</sub>	6	6
CM <sub>1</sub> D	>100	>100	CM <sub>3</sub> DS <sub>1.5</sub>	4	6
CM <sub>1</sub> DS <sub>0.5</sub>	37	8	CM <sub>3</sub> DS <sub>2</sub>	2	1.5
CM <sub>1</sub> DS <sub>0.75</sub>	24	2.5	CM <sub>2</sub> DPhS1	12	2.4
CM <sub>1</sub> DS <sub>1</sub>	20	1	CM <sub>2</sub> DES1	18	3.8
CM <sub>1</sub> DS <sub>1.5</sub>	3	0.15	CM <sub>2</sub> DPheS2	4	0.3
CM <sub>1</sub> DS <sub>2</sub>	1	0.08	CM <sub>3</sub> DTyrS2	1.8	0.15
CM <sub>1</sub> DSex	1	0.035	CM <sub>1</sub> DPalmS1	1.4	6
CM <sub>2</sub> D	>100	>100	CM <sub>1</sub> DOleicS1	2	9
CM <sub>2</sub> DS <sub>0.5</sub>	7	1	DS commercial	>100	>100
CM <sub>2</sub> DS <sub>0.75</sub>	5	0.7	DS <sub>0.5</sub> equiv	>100	>100
CM <sub>2</sub> DS <sub>1</sub>	2	0.5	DS <sub>0.25</sub> equiv	>100	>100
CM <sub>2</sub> DS <sub>1.5</sub>	2	0.1	DS <sub>0.125</sub> equiv	>100	>100
CM <sub>2</sub> DS <sub>2</sub>	2	0.05	Dextran T40	>100	>100